Amolyt Pharma

Amolyt Pharma is dedicated to creating best-in-class treatment options that significantly improve the quality of life for individuals with rare endocrine disorders.

Founded by a team with extensive experience in both peptide drug development and the endocrine therapeutic area, Amolyt combines deep scientific expertise with an unwavering focus on patient needs.The company’s lead program is a groundbreaking therapy currently in late-stage clinical trials for hypoparathyroidism, a severe condition characterized by calcium imbalance. Existing treatments often carry long-term risks, such as kidney damage or adverse effects on bone health, posing additional challenges for a population already predisposed to osteoporosis due to age and gender factors.

Amolyt’s innovative approach addresses these issues by restoring calcium balance in a more physiological and effective manner, potentially offering a transformative solution without the complications associated with traditional therapies. By tackling these critical unmet needs, Amolyt Pharma is aimed at redefining care for hypoparathyroidism and setting a new standard in endocrine disorder treatment.